Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 1/2008

01.01.2008 | grassi prize finalist

Radiofrequency Ablation Versus Surgical Resection for the Treatment of Hepatocellular Carcinoma in Cirrhosis

verfasst von: Alfredo Guglielmi, Andrea Ruzzenente, Alessandro Valdegamberi, Silvia Pachera, Tommaso Campagnaro, Mirko D’Onofrio, Enrico Martone, Paola Nicoli, Calogero Iacono

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Background and Aims

Percutaneous radiofrequency ablation (RFA) demonstrated good results for the treatment of hepatocellular carcinoma (HCC) in cirrhotic patients; it is still not clear whether the overall survival and disease-free survival after RFA are comparable with surgical resection. The aims of this study are to compare the overall survival and disease-free survival in two groups of cirrhotic patients with HCC submitted to surgery or RFA.

Methods

Two hundred cirrhotic patients with HCCs smaller than 6 cm were included in this retrospective study: 109 underwent RFA and 91 underwent surgical resection at a single Division of Surgery of University of Verona.

Results

Median follow-up time was 27 months. Overall survival was significantly longer in the resection group in comparison with the RFA group with a median survival of 57 and 28 months, respectively (P = 0.01). In Child–Pugh class B patients and in patients with multiple HCC, survival was not significantly different between the two groups. In patients with HCC smaller than 3 cm, the overall survival and disease-free survival for RFA and resection were not significantly different in univariate and multivariate analysis. Whereas in patients with HCC greater than 3 cm, surgery showed improvement in outcome in both univariate and multivariate analysis.

Conclusions

Surgical resection significantly improves the overall survival and disease-free survival in comparison with RFA. In a selected group of patients (Child–Pugh class B, multiple HCC, or in HCC ≤3 cm), the results between the two treatments did not show significant differences.
Literatur
1.
Zurück zum Zitat Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9(2):191–211.PubMedCrossRef Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9(2):191–211.PubMedCrossRef
2.
Zurück zum Zitat Carr B. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004;127(5 Suppl 1):S218–S224.PubMedCrossRef Carr B. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004;127(5 Suppl 1):S218–S224.PubMedCrossRef
3.
Zurück zum Zitat Poon RT, Fan ST, Tsang FH, Wong. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon’s perspective. Ann Surg 2002;235(4):466–486.PubMedCrossRef Poon RT, Fan ST, Tsang FH, Wong. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon’s perspective. Ann Surg 2002;235(4):466–486.PubMedCrossRef
4.
Zurück zum Zitat Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 2006;141(2):181–190.PubMedCrossRef Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 2006;141(2):181–190.PubMedCrossRef
5.
Zurück zum Zitat Ng KKC, Lam CM, Poon RT, et al. Thermal ablative therapy for malignant liver tumors: a critical appraisal. J Gastroenterol Hepatol 2003;18:616–629.PubMedCrossRef Ng KKC, Lam CM, Poon RT, et al. Thermal ablative therapy for malignant liver tumors: a critical appraisal. J Gastroenterol Hepatol 2003;18:616–629.PubMedCrossRef
6.
Zurück zum Zitat Curley S. Radiofrequency ablation of malignant liver tumors. Ann Surg Oncol 2003;10:338–347.PubMedCrossRef Curley S. Radiofrequency ablation of malignant liver tumors. Ann Surg Oncol 2003;10:338–347.PubMedCrossRef
7.
Zurück zum Zitat Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, Cavallari A. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg 2004;240(1):102–107.PubMedCrossRef Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, Cavallari A. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg 2004;240(1):102–107.PubMedCrossRef
8.
Zurück zum Zitat Hong SN, Lee SY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Rhee JC, Choi D, Lim HK, Lee KW, Joh JW. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol 2005;39(3):247–252.PubMedCrossRef Hong SN, Lee SY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Rhee JC, Choi D, Lim HK, Lee KW, Joh JW. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol 2005;39(3):247–252.PubMedCrossRef
9.
Zurück zum Zitat Wakai T, Shirai Y, Suda T, Yokoyama N, Sakata J, Cruz P, Kawai H, Matsuda Y, Watanabe M, Aoyagi Y, Hatakeyama K. Long-term outcomes of hepatectomy vs percutaneous ablation for treatment of hepatocellular carcinoma < or =4 cm. World J Gastroenterol 2006;12(4):546–552.PubMed Wakai T, Shirai Y, Suda T, Yokoyama N, Sakata J, Cruz P, Kawai H, Matsuda Y, Watanabe M, Aoyagi Y, Hatakeyama K. Long-term outcomes of hepatectomy vs percutaneous ablation for treatment of hepatocellular carcinoma < or =4 cm. World J Gastroenterol 2006;12(4):546–552.PubMed
10.
Zurück zum Zitat Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421–430.PubMedCrossRef Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421–430.PubMedCrossRef
11.
Zurück zum Zitat Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207–214.PubMedCrossRef Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207–214.PubMedCrossRef
12.
Zurück zum Zitat El-Serag HB, Mallat DB, Rabeneck L. Management of the single liver nodule in a cirrhotic patient: a decision analysis model. J Gastroenterol 2005;39(2):152–159. El-Serag HB, Mallat DB, Rabeneck L. Management of the single liver nodule in a cirrhotic patient: a decision analysis model. J Gastroenterol 2005;39(2):152–159.
13.
Zurück zum Zitat Taura K, Ikai I, Hatano E, Fujii H, Uyama N, Shimahara Y. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. Ann Surg 2006;244(2):265–273.PubMedCrossRef Taura K, Ikai I, Hatano E, Fujii H, Uyama N, Shimahara Y. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. Ann Surg 2006;244(2):265–273.PubMedCrossRef
14.
Zurück zum Zitat Hashikura Y, Kawasaki S, Terada M, et al. Long-term results of living-related donor liver graft transplantation: a single center analysis of 110 patients. Transplantation 2001;72:95–99.PubMedCrossRef Hashikura Y, Kawasaki S, Terada M, et al. Long-term results of living-related donor liver graft transplantation: a single center analysis of 110 patients. Transplantation 2001;72:95–99.PubMedCrossRef
15.
Zurück zum Zitat Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, Sarli D, Schiavo M, Garbagnati F, Marchiano A, Spreafico C, Camerini T, Mariani L, Miceli R, Andreola S. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004;240(5):900–909.PubMedCrossRef Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, Sarli D, Schiavo M, Garbagnati F, Marchiano A, Spreafico C, Camerini T, Mariani L, Miceli R, Andreola S. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004;240(5):900–909.PubMedCrossRef
16.
Zurück zum Zitat Grazi GL, Ercolani G, Pierangeli F, Del Gaudio M, Cescon M, Cavallari A, Mazziotti A. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 2001;234(1):71–78.PubMedCrossRef Grazi GL, Ercolani G, Pierangeli F, Del Gaudio M, Cescon M, Cavallari A, Mazziotti A. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 2001;234(1):71–78.PubMedCrossRef
17.
Zurück zum Zitat Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann Surg 2002;236(5):602–611.PubMedCrossRef Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann Surg 2002;236(5):602–611.PubMedCrossRef
18.
Zurück zum Zitat Guglielmi A, Ruzzenente A, Battocchia A, Tonon A, Fracastoro G, Cordiano C. Radiofrequency ablation of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology 2003;50:480–484.PubMed Guglielmi A, Ruzzenente A, Battocchia A, Tonon A, Fracastoro G, Cordiano C. Radiofrequency ablation of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology 2003;50:480–484.PubMed
19.
Zurück zum Zitat Chen MS, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243(3):321–328.PubMedCrossRef Chen MS, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243(3):321–328.PubMedCrossRef
20.
Zurück zum Zitat Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40(6):1352–1360.PubMedCrossRef Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40(6):1352–1360.PubMedCrossRef
21.
Zurück zum Zitat Guglielmi A, Ruzzenente A, Sandri M, Pachera S, Pedrazzani C, Tasselli S, Iacono C. Radiofrequency ablation for HCC in cirrhotic patients: prognostic factors for survival. J Gastrointest Surg 2007;11(2):143–149, Feb.PubMedCrossRef Guglielmi A, Ruzzenente A, Sandri M, Pachera S, Pedrazzani C, Tasselli S, Iacono C. Radiofrequency ablation for HCC in cirrhotic patients: prognostic factors for survival. J Gastrointest Surg 2007;11(2):143–149, Feb.PubMedCrossRef
22.
Zurück zum Zitat Toyosaka A, Okamoto E, Mitsunobu M, Oriyama T, Nakao N, Miura K. Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as efferent vessel. Am J Gastroenterol 1996;91(8):1610–1615.PubMed Toyosaka A, Okamoto E, Mitsunobu M, Oriyama T, Nakao N, Miura K. Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as efferent vessel. Am J Gastroenterol 1996;91(8):1610–1615.PubMed
Metadaten
Titel
Radiofrequency Ablation Versus Surgical Resection for the Treatment of Hepatocellular Carcinoma in Cirrhosis
verfasst von
Alfredo Guglielmi
Andrea Ruzzenente
Alessandro Valdegamberi
Silvia Pachera
Tommaso Campagnaro
Mirko D’Onofrio
Enrico Martone
Paola Nicoli
Calogero Iacono
Publikationsdatum
01.01.2008
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 1/2008
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-007-0392-8

Weitere Artikel der Ausgabe 1/2008

Journal of Gastrointestinal Surgery 1/2008 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.